Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

Company Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Key Stats

• Today's Range: $1.05 to $1.12
• 50-Day Range: $1.07 to $1.96
• 52-Week Range: $0.73 to $2.33
• Volume: 37,307 shs
• Average Volume: 79,126 shs
• Market Capitalization: $26.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Buy

Accelerate Diagnostics Stock Analysis - MarketRank™

Accelerate Diagnostics scored higher than 69% of companies evaluated by MarketBeat, and ranked 373rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Accelerate Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Accelerate Diagnostics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.30) to ($2.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Accelerate Diagnostics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Accelerate Diagnostics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.67% of the float of Accelerate Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Accelerate Diagnostics has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Accelerate Diagnostics has recently decreased by 17.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Accelerate Diagnostics does not currently pay a dividend.

Dividend Growth

Accelerate Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -1.62

Percentage of Shares Shorted

2.67% of the float of Accelerate Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Accelerate Diagnostics has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Accelerate Diagnostics has recently decreased by 17.61%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Accelerate Diagnostics this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Accelerate Diagnostics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $314,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

43.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 17.14% of the stock of Accelerate Diagnostics is held by institutions.

AXDX Stock Analysis - Frequently Asked Questions

How have AXDX shares performed this year?

Accelerate Diagnostics' stock was trading at $1.20 at the beginning of the year. Since then, AXDX stock has decreased by 10.8% and is now trading at $1.07.
View the best growth stocks for 2025 here.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced its quarterly earnings results on Tuesday, November, 9th. The medical research company reported ($1.50) EPS for the quarter, beating analysts' consensus estimates of ($3.50) by $2.00. The medical research company had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.51 million.

When did Accelerate Diagnostics' stock split?

Shares of Accelerate Diagnostics reverse split on the morning of Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Fluidigm (FLDM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 1/21/2025
• Next Earnings (Estimated): 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:AXDX
• CUSIP: N/A
• CIK: 727207
• Web: acceleratediagnostics.com
• Phone: (520) 365-3100
• Fax: 520-269-6580
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.00
• High Stock Price Target: $1.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: -6.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-61,620,000.00
• Net Margins: -471.83%
• Pretax Margin: -444.14%
• Return on Equity: N/A
• Return on Assets: -191.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.50
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $12.06 million
• Price / Sales: 2.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.37) per share
• Price / Book: -0.78

Miscellaneous

• Outstanding Shares: 25,040,000
• Free Float: 14,125,000
• Market Cap: $26.79 million
• Optionable: Optionable
• Beta: 0.59